Austrian Newborn Screening Program: a perspective of five decades

References

[1] Abrams L, Cronister A, Brown WT, Tassone F, Sherman SL, Finucane B, et al. Newborn, carrier, and early childhood screening recommendations for fragile X. Pediatrics. 2012;130:1126–35.10.1542/peds.2012-0693Search in Google Scholar

[2] Beck M. Therapy for lysosomal storage disorders. IUBMB Life. 2010;62:33–40.Search in Google Scholar

[3] Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. Lancet 1953;265:812–3.10.1016/S0140-6736(53)90473-5Search in Google Scholar

[4] Bombard Y, Miller FA, Hayeems RZ, Avard D, Knoppers BM. Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. Eur J Hum Genet. 2010;18:751–60.10.1038/ejhg.2010.13Search in Google Scholar PubMed PubMed Central

[5] Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2012;129:597–604; quiz 605–596.10.1016/j.jaci.2011.12.964Search in Google Scholar PubMed PubMed Central

[6] Cavazzana-Calvo M, Andre-Schmutz I, Fischer A. Haematopoietic stem cell transplantation for SCID patients: where do we stand? Br J Haematol. 2013;160:146–52.10.1111/bjh.12119Search in Google Scholar PubMed

[7] Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003;49:1797–817.10.1373/clinchem.2003.022178Search in Google Scholar PubMed

[8] Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem. 1993;39: 66–71.10.1093/clinchem/39.1.66Search in Google Scholar

[9] Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, et al. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122:e39–45.10.1542/peds.2007-2222Search in Google Scholar PubMed

[10] Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009; 124:e1116–25.10.1542/peds.2008-3667Search in Google Scholar PubMed

[11] Dajnoki A, Fekete G, Keutzer J, Orsini JJ, De Jesus VR, Chien YH, et al. Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry. Clin Chim Acta. 2010;411:1428–31.10.1016/j.cca.2010.03.009Search in Google Scholar PubMed

[12] Dajnoki A, Muhl A, Fekete G, Keutzer J, Orsini J, Dejesus V, et al. Newborn screening for Pompe disease by measuring acid alpha-glucosidase activity using tandem mass spectrometry. Clin Chem. 2008;54:1624–9.10.1373/clinchem.2008.107722Search in Google Scholar PubMed

[13] De Jesus VR, Zhang XK, Keutzer J, Bodamer OA, Muhl A, Orsini JJ, et al. Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. Clin Chem. 2009;55:158–64.10.1373/clinchem.2008.111864Search in Google Scholar PubMed

[14] Dercksen M, Duran M, Ijlst L, Mienie LJ, Reinecke CJ, Ruiter JP, et al. Clinical variability of isovaleric acidemia in a genetically homogeneous population. J Inherit Metab Dis. 2012;35:1021–9.10.1007/s10545-012-9457-2Search in Google Scholar PubMed

[15] Grunert SC, Wendel U, Lindner M, Leichsenring M, Schwab KO, Vockley J, et al. Clinical and neurocognitive outcome in symptomatic isovaleric acidemia. Orphanet J Rare Dis. 2012;7:9.10.1186/1750-1172-7-9Search in Google Scholar PubMed PubMed Central

[16] Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006;117: 1915–21.10.1542/peds.2005-2294Search in Google Scholar PubMed

[17] Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338–43.10.1542/peds.32.3.338Search in Google Scholar

[18] Haynes CA, De Jesus VR. Improved analysis of C26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening. Clin Chim Acta. 2012;413:1217–21.10.1016/j.cca.2012.03.026Search in Google Scholar PubMed

[19] Item CB, Mercimek-Mahmutoglu S, Battini R, Edlinger-Horvat C, Stromberger C, Bodamer O, et al. Characterization of seven novel mutations in seven patients with GAMT deficiency. Hum Mutat. 2004;23:524.10.1002/humu.9238Search in Google Scholar PubMed

[20] Item CB, Stockler-Ipsiroglu S, Stromberger C, Muhl A, Alessandri MG, Bianchi MC, et al. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am J Hum Genet. 2001;69:1127–33.10.1086/323765Search in Google Scholar PubMed PubMed Central

[21] Kasper DC, Ratschmann R, Metz TF, Mechtler TP, Moslinger D, Konstantopoulou V, et al. The national Austrian newborn screening program-eight years experience with mass spectrometry. Past, present, and future goals. Wien Klin Wochenschr. 2010;122:607–13.10.1007/s00508-010-1457-3Search in Google Scholar PubMed

[22] Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med. 2003;348:50–8.10.1056/NEJMra013182Search in Google Scholar

[23] Knoll E, Wehle E, Thalhammer O. Psychometry and psychological observations in early treated children with phenylketonuria (PKU) during 12 years (author’s transl). Klin Padiatr. 1980;192:599–607.10.1055/s-2008-1035650Search in Google Scholar

[24] Leung DG, Wagner KR. Therapeutic advances in muscular dystrophy. Ann Neurol. 2013;74:404–11.10.1002/ana.23989Search in Google Scholar

[25] Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis. 2012;35:603–11.Search in Google Scholar

[26] Lyon E, Laver T, Yu P, Jama M, Young K, Zoccoli M, et al. A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J Mol Diagn. 2010;12:505–11.10.2353/jmoldx.2010.090229Search in Google Scholar

[27] McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med. 2011;13:230–54.10.1097/GIM.0b013e31820d5e67Search in Google Scholar

[28] Mechtler TP, Metz TF, Muller HG, Ostermann K, Ratschmann R, De Jesus VR, et al. Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;908:9–17.10.1016/j.jchromb.2012.09.012Search in Google Scholar

[29] Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 2012;379:335–41.10.1016/S0140-6736(11)61266-XSearch in Google Scholar

[30] Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc. 1999;281: 249–54.10.1001/jama.281.3.249Search in Google Scholar PubMed

[31] Mendell JR, Shilling C, Leslie ND, Flanigan KM, al-Dahhak R, Gastier-Foster J, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304–13.10.1002/ana.23528Search in Google Scholar PubMed

[32] Metz TF, Mechtler TP, Orsini JJ, Martin M, Shushan B, Herman JL, et al. Simplified newborn screening protocol for lysosomal storage disorders. Clin Chem. 2011;57:1286–94.10.1373/clinchem.2011.164640Search in Google Scholar PubMed

[33] Mutter-Kind Pass (Mother-child booklet). Austrian Federal Ministry of Health.http://www.bmg.gv.at/home/Schwerpunkte/Praevention/Eltern_und_Kind/Mutter_Kind_Pass.Search in Google Scholar

[34] Orsini JJ, Morrissey MA, Slavin LN, Wojcik M, Biski C, Martin M, et al. Implementation of newborn screening for Krabbe disease: population study and cutoff determination. Clin Biochem. 2009;42:877–84.10.1016/j.clinbiochem.2009.01.022Search in Google Scholar

[35] Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. Mol Diagn Ther. 2007;11:381–4.10.1007/BF03256261Search in Google Scholar

[36] Ross LF, Waggoner DJ. Parents: critical stakeholders in expanding newborn screening. J Pediatr. 2012;161:385–9.10.1016/j.jpeds.2012.04.035Search in Google Scholar

[37] Scheibenreiter S. Obituary – Prof. Dr. Otto Thalhammer. Screening 1995;4:55–6.10.1016/0925-6164(95)90004-7Search in Google Scholar

[38] Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics. 2009; 123:1191–207.10.1542/peds.2008-0635Search in Google Scholar PubMed PubMed Central

[39] Stöckler-Ipsiroglu S, Bodamer O, Möslinger D, Mühl A. Report: Austrian Newborn Screening. 2000.Search in Google Scholar

[40] Thalhammer O. Toxoplasmosis investigation of pregnant women and newborn infants (author’s transl). Wien Klin Wochenschr. 1975;87:676–81.Search in Google Scholar

[41] Thalhammer O. 21 years “Austrian Program for Early Detection of Congenital Metabolic Abnormalities.” Did the screening programs also contribute scientific knowledge?. Wien Klin Wochenschr. 1988;100:641–5.Search in Google Scholar

[42] Thalhammer O, Getreuer V. Information on the “Vienna test program” for the early detection of phenylketonuria. Wien Klin Wochenschr. 1966;78:440–2.Search in Google Scholar

[43] Thalhammer O, Scheibenreiter S, Biedl E. Austrian program for the early detection of inborn errors of metabolism. Wien Klin Wochenschr. 1970;82:1–6.Search in Google Scholar

[44] Thalhammer O, Scheibenreiter S, Knoll E, Wehle E, Schon R. 12 years Austrian newborn screening for inborn errors of metabolism. Results with special reference to phenylketonuria, hyperphenylalaninemia and histidinemia (author’s transl). Klin Padiatr. 1980;192:589–98.10.1055/s-2008-1035649Search in Google Scholar PubMed

[45] Thalhammer O, Scheibenreiter S, Schon R, Knoll E, Schmierer G. 5 years of the Austrian program for the early detection of inborn errors of metabolism. Activity report. Wien Klin Wochenschr. 1972;84:3–12.Search in Google Scholar

[46] Timmermans S, Buchbinder M. Patients-in-waiting: living between sickness and health in the genomics era. J Health Soc Behav. 2010;51:408–23.10.1177/0022146510386794Search in Google Scholar PubMed

[47] Turgeon CT, Magera MJ, Cuthbert CD, Loken PR, Gavrilov DK, Tortorelli S, et al. Determination of total homocysteine, methylmalonic acid, and 2-methylcitric acid in dried blood spots by tandem mass spectrometry. Clin Chem. 2010;56: 1686–95.10.1373/clinchem.2010.148957Search in Google Scholar PubMed

[48] Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics. 2003;111:1399–406.10.1542/peds.111.6.1399Search in Google Scholar PubMed

[49] Sommerburg O, Lindner M, Muckenthaler M, Kohlmueller D, Leible S, Feneberg R, et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis. 2010;33:S263–71.10.1007/s10545-010-9174-7Search in Google Scholar PubMed

[50] Stockler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet. 1996;348:789–90.10.1016/S0140-6736(96)04116-5Search in Google Scholar

[51] Stromberger C, Bodamer OA, Stockler-Ipsiroglu S. Clinical characteristics and diagnostic clues in inborn errors of creatine metabolism. J Inherit Metab Dis. 2003;26:299–308.10.1023/A:1024453704800Search in Google Scholar

[52] Vernooij-van Langen AM, Loeber JG, Elvers B, Triepels RH, Gille JJ, Van der Ploeg CP, et al. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study. Thorax. 2012;67:289–95.10.1136/thoraxjnl-2011-200730Search in Google Scholar

[53] Weissel M, Fritzsche H, Hofer R, Frisch H, Thalhammer O. Screening for congenital hypothyroidism. Lancet. 1976; 2:1245.10.1016/S0140-6736(76)91170-3Search in Google Scholar

[54] Widhalm K, Virmani K. Long-term follow-up of 58 patients with histidinemia treated with a histidine-restricted diet: no effect of therapy. Pediatrics 1994;94:861–6.10.1542/peds.94.6.861Search in Google Scholar

[55] Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med. 2003;348:2304–12.10.1056/NEJMoa025225Search in Google Scholar PubMed